Yu GR - Search Results

1

EFNA1 ligand and its receptor EphA2: potential biomarkers for hepatocellular carcinoma.

Cui XD, Lee MJ, Yu GR, Kim IH, Yu HC, Song EY, Kim DG. Cui XD, et al. Among authors: yu gr, yu hc. Int J Cancer. 2010 Feb 15;126(4):940-9. doi: 10.1002/ijc.24798. Int J Cancer. 2010. PMID: 19642143

2

Genome-wide expression patterns associated with oncogenesis and sarcomatous transdifferentation of cholangiocarcinoma.

Seol MA, Chu IS, Lee MJ, Yu GR, Cui XD, Cho BH, Ahn EK, Leem SH, Kim IH, Kim DG. Seol MA, et al. Among authors: yu gr. BMC Cancer. 2011 Feb 19;11:78. doi: 10.1186/1471-2407-11-78. BMC Cancer. 2011. PMID: 21333016 Free PMC article.

3

Pro-oncogenic potential of NM23-H2 in hepatocellular carcinoma.

Lee MJ, Xu DY, Li H, Yu GR, Leem SH, Chu IS, Kim IH, Kim DG. Lee MJ, et al. Among authors: yu gr. Exp Mol Med. 2012 Mar 31;44(3):214-24. doi: 10.3858/emm.2012.44.3.016. Exp Mol Med. 2012. PMID: 22192927 Free PMC article.

4

Activation of mammalian target of rapamycin complex 1 (mTORC1) and Raf/Pyk2 by growth factor-mediated Eph receptor 2 (EphA2) is required for cholangiocarcinoma growth and metastasis.

Cui XD, Lee MJ, Kim JH, Hao PP, Liu L, Yu GR, Kim DG. Cui XD, et al. Among authors: yu gr. Hepatology. 2013 Jun;57(6):2248-60. doi: 10.1002/hep.26253. Hepatology. 2013. PMID: 23315987

5

Disruption of a regulatory loop between DUSP1 and p53 contributes to hepatocellular carcinoma development and progression.

Hao PP, Li H, Lee MJ, Wang YP, Kim JH, Yu GR, Lee SY, Leem SH, Jang KY, Kim DG. Hao PP, et al. Among authors: yu gr. J Hepatol. 2015 Jun;62(6):1278-86. doi: 10.1016/j.jhep.2014.12.033. Epub 2015 Jan 21. J Hepatol. 2015. PMID: 25617504

6

OIP5, a target of miR-15b-5p, regulates hepatocellular carcinoma growth and metastasis through the AKT/mTORC1 and β-catenin signaling pathways.

Li H, Zhang J, Lee MJ, Yu GR, Han X, Kim DG. Li H, et al. Among authors: yu gr. Oncotarget. 2017 Mar 14;8(11):18129-18144. doi: 10.18632/oncotarget.15185. Oncotarget. 2017. PMID: 28184024 Free PMC article.

7

CTHRC1 activates pro-tumorigenic signaling pathways in hepatocellular carcinoma.

Wang Y, Lee M, Yu G, Lee H, Han X, Kim D. Wang Y, et al. Oncotarget. 2017 Oct 27;8(62):105238-105250. doi: 10.18632/oncotarget.22164. eCollection 2017 Dec 1. Oncotarget. 2017. PMID: 29285247 Free PMC article.

8

Genetic and expression alterations in association with the sarcomatous change of cholangiocarcinoma cells.

Yoo HJ, Yun BR, Kwon JH, Ahn HS, Seol MA, Lee MJ, Yu GR, Yu HC, Hong B, Choi K, Kim DG. Yoo HJ, et al. Among authors: yu gr, yu hc. Exp Mol Med. 2009 Feb 28;41(2):102-15. doi: 10.3858/emm.2009.41.2.013. Exp Mol Med. 2009. PMID: 19287191 Free PMC article.

9

Enhancement of parthenolide-induced apoptosis by a PKC-alpha inhibition through heme oxygenase-1 blockage in cholangiocarcinoma cells.

Yun BR, Lee MJ, Kim JH, Kim IH, Yu GR, Kim DG. Yun BR, et al. Among authors: yu gr. Exp Mol Med. 2010 Nov 30;42(11):787-97. doi: 10.3858/emm.2010.42.11.082. Exp Mol Med. 2010. PMID: 20938215 Free PMC article.

10

Lipocalin-2 negatively modulates the epithelial-to-mesenchymal transition in hepatocellular carcinoma through the epidermal growth factor (TGF-beta1)/Lcn2/Twist1 pathway.

Wang YP, Yu GR, Lee MJ, Lee SY, Chu IS, Leem SH, Kim DG. Wang YP, et al. Among authors: yu gr. Hepatology. 2013 Oct;58(4):1349-61. doi: 10.1002/hep.26467. Epub 2013 Aug 7. Hepatology. 2013. PMID: 23696034

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

216 results

Search Page

Filters